keyword
https://read.qxmd.com/read/38705234/factors-influencing-pathological-changes-in-the-liver-tissue-in-hepatitis-b-virus-carriers-with-low-level-viremia
#21
JOURNAL ARTICLE
Haiyan Fu, Hongjuan Li, Yingrong Du, Chunyun Liu, Futao Dang, Xuan Zhang, Danqing Xu, Yachao Mao, Li Feng Wang, Yu Luo, Li Liu
OBJECTIVES: To investigate the optimal timing for initiating antiviral therapy in hepatitis B virus (HBV) carriers with low-level viremia (LLV). METHODS: We retrospectively enrolled 126 HBV carriers with LLV who underwent liver biopsy. Patients' clinical data, routine blood test results, portal vein diameter, splenic vein diameter and thickness, and measurements (LSM) within 1 week before liver biopsy were obtained. Single-factor and multifactor statistical methods were used to analyze factors that affected inflammation and fibrosis in pathological liver tissues...
May 3, 2024: Clinics and Research in Hepatology and Gastroenterology
https://read.qxmd.com/read/38703803/role-of-fxr-in-the-development-of-nafld-and-intervention-strategies-of-small-molecules
#22
REVIEW
Jiachan Long, Yuanhang Xu, Xuerong Zhang, Bingxing Wu, Caiyan Wang
Non-alcoholic fatty liver disease (NAFLD) remains a prevailing etiological agent behind hepatocyte diseases like chronic liver disease. The spectrum of processes involved in NAFLD stages includes hepatic steatosis, non-alcoholic fatty liver, and non-alcoholic steatohepatitis (NASH). Without intervention, the progression of NASH can further deteriorate into cirrhosis and ultimately, hepatocellular carcinoma. The cardinal features that characterize NAFLD are insulin resistance, lipogenesis, oxidative stress and inflammation, extracellular matrix deposition and fibrosis...
May 2, 2024: Archives of Biochemistry and Biophysics
https://read.qxmd.com/read/38703507/alleviation-of-hepatic-insulin-resistance-and-steatosis-with-nmn-via-improving-endoplasmic-reticulum-mitochondria-miscommunication-in-the-liver-of-hfd-mice
#23
JOURNAL ARTICLE
Yumeng Li, Xutong Tian, Qian Yu, Tongtong Bao, Chao Dai, Liang Jiang, Kaimin Niu, Jianying Yang, Shujin Wang, Xin Wu
The interaction between endoplasmic reticulum (ER) and mitochondria has been shown to play a key role in hepatic steatosis during chronic obesity. β-nicotinamide mononucleotide (NMN) has been reported to regulate obesity, however, its molecular mechanism at the subcellular level remains unclear. Here, NMN improved liver steatosis and insulin resistance in chronic high-fat diet (HFD) mice. RNA-seq showed that compared with the liver of HFD mice, NMN intervention enhanced fat digestion and absorption and stimulated the cholesterol metabolism signaling pathways, while impaired insulin resistance and the fatty acid biosynthesis signaling pathways...
May 3, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38702973/a-multicenter-open-label-single-arm-trial-of-the-long-term-safety-of-empagliflozin-treatment-for-refractory-diabetes-mellitus-with-insulin-resistance-empire-02
#24
JOURNAL ARTICLE
Yushi Hirota, Yasumasa Kakei, Junta Imai, Hideki Katagiri, Ken Ebihara, Jun Wada, Junichi Suzuki, Tatsuhiko Urakami, Takashi Omori, Wataru Ogawa
AIMS/INTRODUCTION: Insulin resistance syndrome and lipoatrophic diabetes are rare conditions characterized by the development of treatment-refractory diabetes with severe insulin resistance. We recently conducted a 24 week, multicenter, single-arm trial (EMPIRE-01) that demonstrated a certain level of effectiveness and safety of empagliflozin for these conditions. To evaluate treatment safety over a longer period, we have now performed an additional 28 week trial (EMPIRE-02) that followed on from EMPIRE-01...
May 4, 2024: Journal of Diabetes Investigation
https://read.qxmd.com/read/38702955/torsion-of-the-caudate-lobe-of-the-liver-and-concurrent-necrohemorrhagic-typhlocolitis-in-a-zoo-housed-patagonian-mara
#25
JOURNAL ARTICLE
Catherine Wilson, Steven J Philp, Katherine Hughes
Liver lobe torsion has been reported in many species, with frequent reports in rabbits. Here we describe caudate liver lobe torsion and concurrent necrohemorrhagic typhlocolitis in a Patagonian mara (syn: Patagonian cavy, Patagonian hare, Dolichotis patagonum ). Following acute death, postmortem examination findings included torsion of the hepatic caudate process, which had fibrous adhesions to the pancreas indicating chronicity. The cecal apex and proximal 30 cm of colon had regionally reddened serosa and diffusely roughened and reddened mucosa with brown-red and granular luminal contents...
May 4, 2024: Journal of Veterinary Diagnostic Investigation
https://read.qxmd.com/read/38702350/feasibility-safety-efficacy-and-potential-scaling-up-of-sofosbuvir-based-hcv-treatment-in-central-and-west-africa-tac-anrs-12311-trial
#26
MULTICENTER STUDY
Karine Lacombe, Raoul Moh, Corine Chazallon, Maud Lemoine, Babacar Sylla, Fatoumata Fadiga, Jerôme Le Carrou, Fabienne Marcellin, Charles Kouanfack, Laura Ciaffi, Michelle Tagni Sartre, Magloire Biwole Sida, Alpha Diallo, Joel Gozlan, Moussa Seydi, Viviane Cissé, Christine Danel, Pierre Marie Girard, Thomas d'Aquin Toni, Albert Minga, Sylvie Boyer, Patrizia Carrieri, Alain Attia
Access to Hepatis C treatment in Sub-Saharan Africa is a clinical, public health and ethical concern. The multi-country open-label trial TAC ANRS 12311 allowed assessing the feasibility, safety, efficacy of a specific care model of HCV treatment and retreatment in patients with hepatitis C in Sub Saharan Africa. Between November 2015 and March 2017, with follow-up until mid 2019, treatment-naïve patients with HCV without decompensated cirrhosis or liver cancer were recruited to receive 12 week-treatment with either sofosbuvir + ribavirin (HCV genotype 2) or sofosbuvir + ledipasvir (genotype 1 or 4) and retreatment with sofosbuvir + velpatasvir + voxilaprevir in case of virological failure...
May 3, 2024: Scientific Reports
https://read.qxmd.com/read/38701846/undiagnosed-hiv-in-patients-on-immunosuppressive-medications-presenting-with-hiv-associated-kidney-disease
#27
JOURNAL ARTICLE
Nathaniel Forrester, Jonathan Zhang Suo Keyes, Ronan Cajimat, Yelena Burklin, Mary Ann Kirkconnell Hall, Jason Cobb
Approximately 158,500 adults and adolescents in the United States live with undiagnosed human immunodeficiency virus (HIV). Missed or delayed diagnoses adversely affect disease management and outcomes. This is particularly salient for patients receiving immunosuppressive and immunomodulatory therapy for the management of chronic inflammatory conditions, in which additional immunosuppression may increase the risk and severity of opportunistic infections. Despite this risk, comprehensive HIV testing before the initiation of immunosuppressive therapy is not yet the norm...
May 2024: Southern Medical Journal
https://read.qxmd.com/read/38701255/role-of-cenpf-and-ndc80-in-the-rehabilitation-nursing-of-hepatocellular-carcinoma-and-cirrhosis-an-observational-study
#28
JOURNAL ARTICLE
Wei Jia, Qiaoling Wu, Ruipu Li, Shiyang Hou, Chunbo Kang
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors globally and often develops on the foundation of chronic liver disease or cirrhosis. Cirrhosis is a clinically prevalent chronic progressive liver disease characterized by diffuse liver damage resulting from long-term or repeated actions of 1 or more etiological factors. However, the impact of CENPF and nuclear division cycle 80 (NDC80) genes on rehabilitation nursing of HCC and cirrhosis remains unclear. HCC and cirrhosis datasets GSE63898 and GSE89377 profile files were downloaded from the gene expression omnibus database generated on platforms GPL13667 and GPL6947, respectively...
May 3, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38700075/positive-impact-of-obesity-on-the-prognosis-of-liver-cirrhosis
#29
JOURNAL ARTICLE
Kei Endo, Keisuke Kakisaka, Tamami Abe, Kenji Yusa, Ippeki Nakaya, Takuya Watanabe, Akiko Suzuki, Yuichi Yoshida, Takayoshi Oikawa, Akio Miyasaka, Hidekatsu Kuroda, Takayuki Matsumoto
BACKGROUND AND AIM: The study aims to determine the prognostic impact of obesity, sarcopenic obesity, and dynapenic obesity in patients with chronic liver disease. METHODS: This retrospective observational study enrolled patients with chronic hepatitis (n = 746) and liver cirrhosis (n = 434) without hepatocellular carcinoma at entry. The patients were evaluated for sarcopenia and obesity between April 2016 and April 2022. Obesity was defined as a body mass index of ≥ 25 kg/m2 ...
May 3, 2024: Journal of Gastroenterology and Hepatology
https://read.qxmd.com/read/38700058/peritoneal-dialysis-in-an-end-stage-renal-disease-patient-with-massive-ascites-and-primary-liver-cancer
#30
JOURNAL ARTICLE
Lulu Sun, Chunmei Liang, Yuqin Wang, Hui Li, Lijun Yao, Huajun Jiang
End-stage renal disease (ESRD) coexisted with cirrhosis, ascites, and primary liver cancer represents an extraordinarily rare clinical condition that typically occurs in very late-stage decompensated cirrhosis and is associated with an extremely poor prognosis. We present a case of a 68-year-old male patient with ESRD who experienced various decompensated complications of liver cirrhosis, particularly massive ascites and hepatic space-occupying lesions. Peritoneal dialysis (PD) catheter insertion and continuous ambulatory peritoneal dialysis (CAPD) treatment were successfully performed...
December 2024: Renal Failure
https://read.qxmd.com/read/38699975/pegylated-interferon-alpha-peg-ifn%C3%AE-induced-interstitial-lung-disease-in-a-patient-with-chronic-hepatitis-b-a%C3%A2-case-report-and-literature-review
#31
JOURNAL ARTICLE
Minghui Shi, Shiyao Wang, Yanhong Ren, Ling Zhao, Min Liu, Lulu Yang, Ting Yang
OBJECTIVES: Interferon (IFN)-induced lung injury is a rare but severe complication. Studies are needed to elucidate the demographic characteristics, clinical manifestations, and prognostic features of IFN-induced interstitial lung disease (ILD). CASE REPORT: We report a patient with chronic hepatitis who developed ILD after interferon monotherapy. To further clarify the clinical characteristics of such patients, we searched for cases in which lung injury was documented as a side effect of hepatitis treatment and systematically analyzed all case reports for clinical manifestations, type of treatment, and outcomes...
May 3, 2024: International Journal of Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/38699562/perspective-on-emerging-therapies-to-achieve-functional-cure-of-chronic-hepatitis-b
#32
JOURNAL ARTICLE
Harish Gopalakrishna, Marc G Ghany
PURPOSE OF REVIEW: Advancements in our understanding of the hepatitis B viral (HBV) life cycle have paved the way for novel approaches to treat HBV infection. This review summarizes the various strategies being pursued to achieve a functional cure, defined as loss of hepatitis B surface antigen (HBsAg) and absence of viral replication 6 months off-therapy. RECENT FINDINGS: Direct acting antiviral, host targeting antiviral, and immunological approaches are in various stages of development as treatment for chronic HBV infection...
June 2024: Current Hepatology Reports
https://read.qxmd.com/read/38699531/immediate-postpartum-cessation-of-tenofovir-did-not-increase-risk-of-virological-or-clinical-relapse-in-highly-viremic-pregnant-mothers-with-chronic-hepatitis-b-infection
#33
JOURNAL ARTICLE
Yu Chen, Lung-Yi Mak, Mary H Y Tang, Jingyi Yang, Chun Bong Chow, Ai-Ming Tan, Tao Lyu, Juan Wu, Qingjuan Huang, Hai-Bo Huang, Ka-Shing Cheung, Man-Fung Yuen, Wai-Kay Seto
BACKGROUND & AIMS: Peripartum prophylaxis (PP) with tenofovir disoproxil fumarate (TDF) is the standard of care to prevent mother-to-child transmission of chronic hepatitis B (CHB) infection in mothers who are highly viremic. We investigated the maternal and infant outcomes in a large Chinese cohort of TDF-treated CHB pregnant participants. METHODS: In this prospective study, treatment-naive mothers with CHB and highly viremic (HBV DNA ≥200,000 IU/ml) but without cirrhosis were treated with TDF at 24-28 weeks of pregnancy...
May 2024: JHEP reports: innovation in hepatology
https://read.qxmd.com/read/38699073/predictive-role-of-hepatic-venous-pressure-gradient-in-bleeding-events-among-patients-with-cirrhosis-undergoing-orthotopic-liver-transplantation
#34
JOURNAL ARTICLE
Mikhael Giabicani, Pauline Joly, Stéphanie Sigaut, Clara Timsit, Pauline Devauchelle, Fédérica Dondero, François Durand, Pierre Antoine Froissant, Myriam Lamamri, Audrey Payancé, Aymeric Restoux, Olivier Roux, Tristan Thibault-Sogorb, Shantha Ram Valainathan, Mickaël Lesurtel, Pierre-Emmanuel Rautou, Emmanuel Weiss
BACKGROUND & AIMS: Major bleeding events during orthotopic liver transplantation (OLT) are associated with poor outcomes. The proportion of this risk related to portal hypertension is unclear. Hepatic venous pressure gradient (HVPG) is the gold standard for estimating portal hypertension. The aim of this study was to analyze the ability of HVPG to predict intraoperative major bleeding events during OLT in patients with cirrhosis. METHODS: We retrospectively analyzed a prospective database including all patients with cirrhosis who underwent OLT between 2010 and 2020 and had liver and right heart catheterizations as part of their pre-transplant assessment...
June 2024: JHEP reports: innovation in hepatology
https://read.qxmd.com/read/38698891/gene-by-environment-interaction-in-non-alcoholic-fatty-liver-disease-and-depression-the-role-of-hepatic-transaminases
#35
JOURNAL ARTICLE
Eron G Manusov, Vincent P Diego, Edward Abrego, Kathryn Herklotz, Marcio Almeida, Xi Mao, Sandra Laston, John Blangero, Sarah Williams-Blangero
Non-alcoholic fatty liver disease (NAFLD) encompasses a range of liver conditions, from benign fatty accumulation to severe fibrosis. The global prevalence of NAFLD has risen to 25-30%, with variations across ethnic groups. NAFLD may advance to hepatocellular carcinoma, increases cardiovascular risk, is associated with chronic kidney disease, and is an independent metabolic disease risk factor. Assessment methods for liver health include liver biopsy, magnetic resonance imaging, ultrasound, and vibration-controlled transient elastography (VCTE by FibroScan)...
September 2023: Medical Research Archives
https://read.qxmd.com/read/38698255/predictive-factors-of-90-day-mortality-after-curative-hepatic-resection-for-hepatocellular-carcinoma-a-western-single-center-observational-study
#36
JOURNAL ARTICLE
Sascha Vaghiri, Nadja Lehwald-Tywuschik, Dimitrios Prassas, Sami Alexander Safi, Sinan Kalmuk, Wolfram Trudo Knoefel, Levent Dizdar, Andrea Alexander
PURPOSE: The aim of this study was to identify predictive risk factors associated with 90-day mortality after hepatic resection (HR) in hepatocellular carcinoma (HCC). METHODS: All patients undergoing elective resection for HCC from a single- institutional and prospectively maintained database were included. Multivariate regression analysis was conducted to identify pre- and intraoperative as well as histopathological predictive factors of 90-day mortality after elective HR...
May 3, 2024: Langenbeck's Archives of Surgery
https://read.qxmd.com/read/38697771/tlr8-agonist-selgantolimod-regulates-kupffer-cell-differentiation-status-and-impairs-hbv-entry-into-hepatocytes-via-an-il-6-dependent-mechanism
#37
JOURNAL ARTICLE
Armando Andres Roca Suarez, Marie-Laure Plissonnier, Xavier Grand, Maud Michelet, Guillaume Giraud, Maria Saez-Palma, Anaëlle Dubois, Sarah Heintz, Audrey Diederichs, Nicolaas Van Renne, Thomas Vanwolleghem, Stephane Daffis, Li Li, Nikita Kolhatkar, Yao-Chun Hsu, Jeffrey J Wallin, Audrey H Lau, Simon P Fletcher, Michel Rivoire, Massimo Levrero, Barbara Testoni, Fabien Zoulim
OBJECTIVE: Achieving HBV cure will require novel combination therapies of direct-acting antivirals and immunomodulatory agents. In this context, the toll-like receptor 8 (TLR8) agonist selgantolimod (SLGN) has been investigated in preclinical models and clinical trials for chronic hepatitis B (CHB). However, little is known regarding its action on immune effectors within the liver. Our aim was to characterise the transcriptomic changes and intercellular communication events induced by SLGN in the hepatic microenvironment...
May 2, 2024: Gut
https://read.qxmd.com/read/38697590/novel-blood-and-tissue-based-mitochondrial-d-loop-mutations-detected-in-an-iranian-nafld-patient-cohort
#38
JOURNAL ARTICLE
Sharareh Kamfar, Bardia Danaei, Samane Rahimi, Vahide Zeinali
Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent chronic liver disease characterized by an elusive etiology. In its advanced stages, this condition can pose life-threatening implications. Mitochondrial dysfunction due to its impact on hepatic lipid homeostasis, cytokine release, ROS production, and cell death, contributes to the pathogenesis of NAFLD. Previous research reveals a direct link between NAFLD genetic predictors and mitochondrial dysfunction. The emphasis on the D-loop stems from its association with impaired mtDNA replication, underscoring its crucial role in NAFLD progression...
April 30, 2024: Mitochondrion
https://read.qxmd.com/read/38697358/inflammation-in-alcohol-associated-hepatitis-pathogenesis-and-therapeutic-targets
#39
REVIEW
Dechun Feng, Seonghwan Hwang, Adrien Guillot, Yang Wang, Yukun Guan, Cheng Chen, Luca Maccioni, Bin Gao
Alcohol-associated hepatitis (AH) is an acute-on-chronic liver injury that occurs in patients with chronic alcohol-associated liver disease (ALD). Patients with severe AH have high short-term mortality and lack effective pharmacological therapies. Inflammation is believed to be one of the key factors promoting AH progression and has been actively investigated as therapeutic targets over the last several decades, but no effective inflammatory targets have been identified so far. In this review, we discuss how inflammatory cells and the inflammatory mediators produced by these cells contribute to the development and progression of AH with focus on neutrophils and macrophages...
April 30, 2024: Cellular and Molecular Gastroenterology and Hepatology
https://read.qxmd.com/read/38697356/rassf4-attenuates-metabolic-dysfunction-associated-steatotic-liver-disease-progression-via-hippo-signaling-and-suppresses-hepatocarcinogenesis
#40
JOURNAL ARTICLE
Chaofei Xu, Ting Fang, Jingru Qu, Yahui Miao, Lei Tian, Man Zhang, Hao Zhuang, Bei Sun, Liming Chen
BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a dynamic chronic liver disease closely related to metabolic abnormalities, such as diabetes and obesity. MASLD can further progress to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis and even hepatocellular carcinoma (HCC). However, the mechanisms underlying the progression of MASLD and further progression to liver fibrosis and liver cancer are unknown. METHODS: In this study, we performed transcriptome analysis in livers from mice with MASLD and found suppression of a potential anti-oncogene, RAS association domain protein 4 (RASSF4)...
April 30, 2024: Cellular and Molecular Gastroenterology and Hepatology
keyword
keyword
16711
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.